Soligenix Announces SGX942 for Treatment of Oral Mucositis In Head and Neck Cancer Patients Found to be Safe, Well-Tolerated with Multiple Potential Ancillary Benefits

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!